Director Ra Capital Management, L.P. sold $13,707,361 worth of shares (464,025 units at $29.54) (SEC Form 4)

10/17/25 6:03:01 PM ET

$VOR

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VOR alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last)

(First)

(Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2025		S		42,699	D	$30.55⁽¹⁾	1,848,336⁽²⁾	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/15/2025		S		8,384	D	$30.55⁽¹⁾	82,882⁽²⁾	I	See footnotes⁽³⁾⁽⁵⁾
Common Stock	10/15/2025		S		234	D	$31.17⁽⁶⁾	1,848,102	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/15/2025		S		46	D	$31.17⁽⁶⁾	82,836	I	See footnotes⁽³⁾⁽⁵⁾
Common Stock	10/16/2025		S		111,041	D	$29.32⁽⁷⁾	1,737,061	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/16/2025		S		21,804	D	$29.32⁽⁷⁾	61,032	I	See footnotes⁽³⁾⁽⁵⁾
Common Stock	10/16/2025		S		15,826	D	$30.36⁽⁸⁾	1,721,235	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/16/2025		S		3,108	D	$30.36⁽⁸⁾	57,924	I	See footnotes⁽³⁾⁽⁵⁾
Common Stock	10/16/2025		S		20	D	$31.35	1,721,215	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/16/2025		S		4	D	$31.35	57,920	I	See footnotes⁽³⁾⁽⁵⁾
Common Stock	10/17/2025		S		174,594	D	$29.12⁽⁹⁾	1,546,621	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/17/2025		S		34,284	D	$29.12⁽⁹⁾	23,636	I	See footnotes⁽³⁾⁽⁵⁾
Common Stock	10/17/2025		S		30,758	D	$30.28⁽¹⁰⁾	1,515,863	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/17/2025		S		6,040	D	$30.28⁽¹⁰⁾	17,596	I	See footnotes⁽³⁾⁽⁵⁾
Common Stock	10/17/2025		S		12,691	D	$31	1,503,172	I	See footnotes⁽³⁾⁽⁴⁾
Common Stock	10/17/2025		S		2,492	D	$31	15,104	I	See footnotes⁽³⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last)

(First)

(Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last)

(First)

(Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Nexus Fund, L.P.

(Last)

(First)

(Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last)

(First)

(Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last)

(First)

(Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.15 to $31.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split.

3. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

4. Held directly by the Fund.

5. Held directly by the Nexus Fund.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.17 to $31.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.695 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.80 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.70 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Ms. Sarah Reed, General Counsel of the Adviser, serves on the Issuer's board of directors.

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	10/17/2025
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	10/17/2025
	/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund GP, LLC the General Partner of RA Capital Nexus Fund, L.P.	10/17/2025
	/s/ Peter Kolchinsky, individually	10/17/2025
	/s/ Rajeev Shah, individually	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $VOR alert in real time by email

Recent Analyst Ratings for

$VOR

Date	Price Target	Rating	Analyst
10/15/2025	$64.00	Neutral → Outperform	Robert W. Baird
9/24/2025	$55.00	Hold → Buy	Stifel
6/30/2025	$3.00	Neutral → Buy	H.C. Wainwright
7/26/2022	$18.00	Outperform	Wedbush
4/27/2022	$6.00	Neutral	Goldman
12/17/2021	$26.00	Buy	HC Wainwright & Co.
12/3/2021	$38.00	Outperform	Robert W. Baird
12/3/2021	$38.00	Outperform	Baird

More analyst ratings

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date (Month/Day/Year)

2A. Deemed Execution Date, if any (Month/Day/Year)

3. Transaction Code (Instr. 8)

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

Amount

(A) or (D)

Price

Common Stock

10/15/2025

42,699

$30.55⁽¹⁾

1,848,336⁽²⁾

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/15/2025

8,384

$30.55⁽¹⁾

82,882⁽²⁾

See footnotes⁽³⁾⁽⁵⁾

Common Stock

10/15/2025

234

$31.17⁽⁶⁾

1,848,102

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/15/2025

$31.17⁽⁶⁾

82,836

See footnotes⁽³⁾⁽⁵⁾

Common Stock

10/16/2025

111,041

$29.32⁽⁷⁾

1,737,061

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/16/2025

21,804

$29.32⁽⁷⁾

61,032

See footnotes⁽³⁾⁽⁵⁾

Common Stock

10/16/2025

15,826

$30.36⁽⁸⁾

1,721,235

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/16/2025

3,108

$30.36⁽⁸⁾

57,924

See footnotes⁽³⁾⁽⁵⁾

Common Stock

10/16/2025

$31.35

1,721,215

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/16/2025

$31.35

57,920

See footnotes⁽³⁾⁽⁵⁾

Common Stock

10/17/2025

174,594

$29.12⁽⁹⁾

1,546,621

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/17/2025

34,284

$29.12⁽⁹⁾

23,636

See footnotes⁽³⁾⁽⁵⁾

Common Stock

10/17/2025

30,758

$30.28⁽¹⁰⁾

1,515,863

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/17/2025

6,040

$30.28⁽¹⁰⁾

17,596

See footnotes⁽³⁾⁽⁵⁾

Common Stock

10/17/2025

12,691

$31

1,503,172

See footnotes⁽³⁾⁽⁴⁾

Common Stock

10/17/2025

2,492

$31

15,104

See footnotes⁽³⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Recent Analyst Ratings for

$VOR

Date	Price Target	Rating	Analyst
10/15/2025	$64.00	Neutral → Outperform	Robert W. Baird
9/24/2025	$55.00	Hold → Buy	Stifel
6/30/2025	$3.00	Neutral → Buy	H.C. Wainwright
7/26/2022	$18.00	Outperform	Wedbush
4/27/2022	$6.00	Neutral	Goldman
12/17/2021	$26.00	Buy	HC Wainwright & Co.
12/3/2021	$38.00	Outperform	Robert W. Baird
12/3/2021	$38.00	Outperform	Baird

More analyst ratings

Director Ra Capital Management, L.P. sold $13,707,361 worth of shares (464,025 units at $29.54) (SEC Form 4)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$VOR

Director Ra Capital Management, L.P. sold $13,707,361 worth of shares (464,025 units at $29.54) (SEC Form 4)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$VOR

$VOR
SEC Filings

SEC Form 144 filed by Vor Biopharma Inc.

SEC Form 144 filed by Vor Biopharma Inc.

SEC Form 144 filed by Vor Biopharma Inc.

$VOR
Insider Trading

Large owner Reprogrammed Interchange Llc sold $2,348,744 worth of shares (73,676 units at $31.88), decreasing direct ownership by 6% to 1,204,442 units (SEC Form 4)